UnknownNot Applicable

Risk Evaluation by COronary CTA and Artificial IntelliGence Based fuNctIonal analyZing tEchniques - II

China2,000 participantsStarted 2023-07-03

Plain-language summary

This study is a multicenter, prospective clinical cohort study. The study intends to continuously enroll patients with coronary heart disease. All subjects will undergo coronary CTA (followed by anatomic, functional and radiomics analysis), proteomics research as well as clinical follow-up of cardiovascular events. The purpose of this study is to establish a new, non-invasive cardiovascular disease risk stratification system.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18-80 years * Clinically significant angina pectoris, suspecting coronary artery disease Exclusion Criteria: * Unsuitable for coronary CTA (such as severe renal impairment, uncontrolled thyroid condition, allergic to iodine, etc.) * Without a visible plaque (defined as ≥ 30% stenosis) in major coronary arteries in coronary CTA * Prior history of myocardial infarction or heart failure * Prior history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) * Severe renal or liver failure * Familial hypercholesterolemia * Estimated survival ≤1 year * Malignant tumor * Poor coordinance, unable to follow-up

What they're measuring

Major Adverse Cardiovascular Events

Timeframe: 2 years

Trial details

NCT IDNCT05856110

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09-30

Contact for this trial

Xiaoqun Wang, M.D., Ph.D.

+86 13651839760 xiaoqun_wang@hotmail.com

View on ClinicalTrials.gov More Coronary Artery Disease trials